P-glycoprotein in autoimmune rheumatic diseases

Autoimmunity Reviews

Volumn 14, Issue 7, 2015, Pages 594-600

  Garcia Carrasco M ^a,b   Mendoza Pinto, C ^a,b   Macias Diaz S ^a   Vera Recabarren, M ^c   Vazquez de Lara L ^b   Mendez Martinez S ^a   Soto Santillan P ^a   Gonzalez Ramirez R ^a   Ruiz Arguelles, A ^d,e  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^c Hospital Exequiel González Cortés   (Chile)

^d Laboratorios Clinicos de Puebla   (Mexico)

^e UNIVERSIDAD DE LAS AMÉRICAS PUEBLA   (Mexico)

Author keywords

Flow cytometry; Glucocorticoids; Ineffective therapy; Methotrexate; P glycoprotein; Psoriatic arthritis; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

AMIODARONE; ANTIINFECTIVE AGENT; CEFOPERAZONE; CEFTRIAXONE; CHLORPROMAZINE; CYCLOSPORIN A; GEFITINIB; GLUCOCORTICOID; KETOCONAZOLE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NIFEDIPINE; PROGESTERONE; TACROLIMUS; TAMOXIFEN; VERAPAMIL;

DNA POLYMORPHISM; HUMAN; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; AUTOIMMUNE DISEASE; ENZYME SPECIFICITY; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; RHEUMATIC DISEASES; SUBSTRATE SPECIFICITY;

EID: 84928923724     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.02.006     Document Type: Review

References (57)

1. Picchianti-Diamanti A., Rosado M.M., Scarsella M., Laganà B., D'Amelio R. P-glycoprotein and drug resistance in systemic autoimmune diseases. Int J Mol Sci Mar 20 2014, 15(3):4965-4976.
2. Zhang Y., Kong X., Wang R., Li S., Niu Y., Zhu L., et al. Genetic association of the P-glycoprotein gene ABCB1 polymorphisms with the risk for steroid-induced osteonecrosis of the femoral head in Chinese population. Mol Biol Rep May 2014, 41(5):3135-3146.
3. Yang X.Y., Xu D.H. MDR1(ABCB1) gene polymorphisms associated with steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus. Pharmazie Dec 2007, 62(12):930-932.
4. Gervasini G., Carrillo J.A., Garcia M., San Jose C., Cabanillas A., Benitez J. Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer. Cancer Dec 15 2006, 107(12):2850-2857.
5. Gonzalez T.P., Mucenic T., Brenol J.C., Xavier R.M., Schiengold M., Chies J.A. ABCB1 C1236T, G2677T/A and C3435T polymorphisms in systemic lupus erythematosus patients. Braz J Med Biol Res Sep 2008, 41(9):769-772.
6. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science Jan 26 2007, 315(5811):525-528.
7. Sharom Frances J. Multidrug Resistance Protein (P-Glycoprotein; MDR1) Department of Molecular and Cellular Biology 2005, University of Guelph, Canada.
8. Takatori R., Takahashi K.A., Tokunaga D., Hojo T., Fujioka M., Asano T., et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol 2006, 24(5):546-554.
9. Sánchez--Suarez L.P., Benítez-Bribiesca L. Procesos biomoleculares de la resistencia a drogas. Cancerología 2006, 1:187-199.
10. Zaher H., Khan A.A., Palandra J., Brayman T.G., Yu L., Ware J.A. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 2006, 3(1):55-61.
11. van der Heijden J.W., Oerlemans R., Tak P.P., Assaraf Y.G., Kraan M.C., Scheffer G.L., et al. Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. Arthritis Rheum Mar 2009, 60(3):669-677.
12. Lagas J.S., van der Kruijssen C.M., van de Wetering K., Beijnen J.H., Schinkel A.H. Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos Jan 2009, 37(1):129-136.
13. Kartner N., Riordan J.R., Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science Sep 23 1983, 221(4617):1285-1288.
14. Higgins C.F. Multiple molecular mechanisms for multidrug resistance transporters. Nature Apr 12 2007, 446(7137):749-757.
15. Pao S.S., Paulsen I.T., Saier M.H. Major facilitator superfamily. Microbiol Mol Biol Rev Mar 1998, 62(1):1-34.
16. Tsujimura S., Saito K., Nakayamada S., Nakano K., Tanaka Y. Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum Jun 2005, 52(6):1676-1683.
17. Tsujimura S., Tanaka Y. Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. Clin Exp Nephrol Feb 2012, 16(1):102-108.
18. Tanaka Y., Tsujimura S. Multi-drug resistance in the treatments of autoimmune diseases. Nihon Rinsho Meneki Gakkai Kaishi Oct 2006, 29(5):319-324.
19. Llorente L., Richaud-Patin Y., Díaz-Borjón A., Alvarado de la Barrera C., Jakez-Ocampo J., de la Fuente H., et al. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine Jan 2000, 67(1):30-39.
20. Hirsch-Ernst K.I., Ziemann C., Foth H., Kozian D., Schmitz-Salue C., Kahl G.F. Induction of mdr1b mRNA and P-glycoprotein expression by tumor necrosis factor alpha in primary rat hepatocyte cultures. J Cell Physiol Sep 1998, 176(3):506-515.
21. Richaud-Patin Y., Soto-Vega E., Jakez-Ocampo J., Llorente L. P-glycoprotein in autoimmune diseases. Autoimmun Rev Mar 2004, 3(3):188-192.
22. Ai A.L., Kronfol Z., Seymour E., Bolling S.F. Effects of mood state and psychosocial functioning on plasma Interleukin-6 in adult patients before cardiac surgery. Int. J Psychiatry Med 2005, 35(4):363-376.
23. Cortada C.M., Gil A., Goncalves S., Sambuelli A., Rubio M., Carballo M. Funcionalidad de la glicoproteina p linfocitaria en la colitis ulcerosa. Medicina (B Aires) 2009, 69:437-441.
24. Lu M.C., Lai N.S., Li K.J., Hsieh S.C., Wu C.H., Yu C.L. Increased multidrug resistance-associated protein activity in mononuclear cells of patients with systemic lupus erythematosus. Clin Exp Rheumatol 2008, 26(4):638-645.
25. Linardi R.L., Natalini C.C. Multi-drug resistance (MDR1) gene and P-glycoprotein influence on pharmacokinetic and pharmacodymanic of therapeutic drugs. Ciênc Rural 2006, 36(1):336-341.
26. Fernández J., Crombet O., Villares I., Pons R. Resistencia a drogas mediada por la glicoproteína p. Rev Cuba Oncol 1998, 14(2):111-120.
27. Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science Mar 27 2009, 323(5922):1718-1722.
28. Cortada C.M., Escobar A., Bramuglia G.F., Niselman A.V., Carballo M.A., Rubio M.C. Lymphocyte P-glycoprotein variability in healthy individuals. Medicina (B Aires) 2009, 69(6):619-624.
29. Ospina J., Álvarez A.M., Carmona H. Papel de las proteínas de membrana en la resistencia al tratamiento médico de la epilepsia. Rev Med Risaralda 2006, 12(1):40-44.
30. Suzuki K., Saito K., Tsujimura S., Nakayamada S., Yamaoka K., Sawamukai N., et al. Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. J Rheumatol Mar 2010, 37(3):512-520.
31. Salmon S.E., Dalton W.S. Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypothesis. J Rheumatol Suppl Mar 1996, 44:97-101.
32. Tanaka Y., Tsujimura S. Clinical implication of cyclosporin for rheumatoid arthritis. Nihon Rinsho Dec 2002, 60(12):2345-2350.
33. Hidaka T., Suzuki K. The mechanism of the efficiency of leukocytapheresis on rheumatoid arthritis. Ther Apher Aug 1997, 1(3):215-218.
34. Honjo K., Takahashi K.A., Mazda O., Kishida T., Shinya M., Tokunaga D., et al. MDR1a/1b gene silencing enhances drug sensitivity in rat fibroblast-like synoviocytes. J Gene Med Feb 2010, 12(2):219-227.
35. Holló Z., Homolya L., Davis C.W., Sarkadi B. Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta May 11 1994, 1191(2):384-388.
36. Homolya L., Holló Z., Germann U.A., Pastan I., Gottesman M.M., Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem Oct 15 1993, 268(29):21493-21496.
37. Liminga G., Nygren P., Larsson R. Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833. Exp Cell Res Jun 1994, 212(2):291-296.
38. Guzmán-Ruiz O., Guzmán O., Serrano-Sandoval S.N., Pérez-Romano B., Estrada-Marín L., Cedillo-Carvallo B., et al. Selection of healthy volunteers according to their MDR-1 activity does not affect bioavailability of quetiapine 2015, (submitted for publication).
39. García-Carrasco M., Mendoza-Pinto C., Escárcega R.O., Jiménez-Hernández M., Etchegaray Morales I., Munguía Realpozo P., et al. Osteoporosis in patients with systemic lupus erythematosus. Isr Med Assoc J Aug 2009, 11(8):486-491.
40. Rúa-Figueroa I., López-Longo F.J., Calvo-Alén J., Galindo-Izquierdo M., Loza E., García de Yebenes M.J., et al. Registro nacional de pacientes con lupus eritematoso sistémico de la Sociedad Española de Reumatología: objetivos y metodología. Reumatol Clin 2014, 10:17-24.
41. Henmi K., Yoshida M., Yoshikawa N., Hirano T. P-glycoprotein functions in peripheral-blood CD4+ cells of patients with systemic lupus erythematosus. Biol Pharm Bull May 2008, 31(5):873-878.
42. Ragab S.M., Soliman M.A. P-glycoprotein-1 functional activity in CD5+CD7+ and CD20+ lymphocytes in systemic lupus erythematosus children: relation to disease activity, complications and steroid response. Egypt J Immunol 2013, 20(2):101-115.
43. Diaz-Borjon A., Richaud-Patin Y., Alvarado de la Barrera C., Jakez-Ocampo J., Ruiz-Argüelles A., Llorente L. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint Bone Spine Jan 2000, 67(1):40-48.
44. Tsujimura S., Saito K., Tokunaga M., Nakatsuka K., Nakayamada S., Nakano K., et al. Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. Mod Rheumatol 2005, 15(1):28-32.
45. Sakthiswary R., Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus Mar 2014, 23(3):225-235.
46. Gonzalo-Gila E., Galindo-Izquierdo M. Papel del factor de crecimiento transformador-beta (TGF-β) en la fisiopatología de la artritis reumatoide. Reumatol Clin 2014, 10:174-179.
47. Maillefert J.F., Maynadie M., Tebib J.G., Aho S., Walker P., Chatard C., et al. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol May 1996, 35(5):430-435.
48. Tsujimura S., Saito K., Nawata M., Nakayamada S., Tanaka Y. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis Mar 2008, 67(3):380-388.
49. Tsujimura S., Saito K., Nakayamada S., Tanaka Y. Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. Mod Rheumatol Apr 2010, 20(2):139-146.
50. Pawlik A., Wrzesniewska J., Fiedorowicz-Fabrycy I., Gawronska-Szklarz B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther Sep 2004, 42(9):496-503.
51. Drozdzik M., Rudas T., Pawlik A., Kurzawski M., Czerny B., Gornik W., et al. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol Nov 2006, 62(11):933-937.
52. Bohanec Grabar P., Logar D., Lestan B., Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol Nov 2008, 64(11):1057-1068.
53. Harisonds Principles of Internal Medicina 2013, 1072-1085. Mc Graw Hill. 18th ed. D.L. Kasper, A.S. Fauci, D.L. Longo, S.L. Hauser, J.L. Jameson, J.L. Loscalzo (Eds.).
54. Diamanti A.P., Rosado M., Germano V., Scarsella M., Giorda E., Podestà E., et al. Reversion of resistance to immunosuppressive agents in three patients with psoriatic arthritis by cyclosporine A: modulation of P-glycoprotein function. Clin Immunol Jan 2011, 138(1):9-13.
55. Barnes P.J., Adcock I.M. Glucocorticoid resistance in inflammatory diseases. Lancet May 30 2009, 373(9678):1905-1917.
56. Samara S.A., Irshaid Y.M., Mustafa K.N. Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients. Int J Clin Pharmacol Sep 2014, 52(9):746-755.
57. Soto-Vega E., Arroyo C., Richaud-Patin Y., García-Carrasco M., Vázquez-Lavista L.G., Llorente L. P-glycoprotein activity in renal clear cell carcinoma. Urol Oncol 2009, 27(4):363-366.